Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Junshi Biosciences (1877 HK)
Watchlist
213
Analysis
Health Care
•
China
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Shanghai Junshi Biosciences
•
24 Jun 2019 17:04
Junshi Bioscience Lock-Up Expiry: Valuation Still Rich with Few R&D Updates
Shanghai Junshi Bioscience Co. Ltd. (1877 HK) was listed on December 2018 and recorded a stellar debut performance thanks to the NDA approval for...
Ke Yan, CFA, FRM
Follow
427 Views
Share
bullish
•
Alibaba Group Holding
•
22 Jun 2019 12:52
ECM Weekly (22 Jun 2019) - Alibaba, Budweiser Brewing Co, Ascentage, CIMC Vehicle, Impro Precision
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
Zhen Zhou, Toh
542 Views
Share
bullish
•
Ascentage Pharma Group Corp
•
19 Jun 2019 13:02
Ascentage Pharma (亚盛医药) IPO: Updates and Thoughts on HQP1351 (3rd Gen Bcr-Abl TKI)
Ascentage Pharma is pre-marketing the USD 200 - 300 million IPO to list in Hong Kong. In our previous insight, we highlight the company's key...
Ke Yan, CFA, FRM
Follow
744 Views
Share
bearish
•
MabPharm
•
20 May 2019 15:09
Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
Arun George
Follow
584 Views
Share
bullish
•
Innovent Biologics Inc
•
11 Apr 2019 09:11
Keytruda Approved for Lung Cancer Treatment in China - A Review of PD-1 Battle Field
Anti-PD-1 monoclonal antibody (mAb) is a hotly contested immunotherapy area in China, with seven companies working on clinical trials covering...
Ke Yan, CFA, FRM
Follow
631 Views
Share
First
Previous
35
36
37
38
39
40
41
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x